234 related articles for article (PubMed ID: 24297706)
1. Macitentan: first global approval.
Patel T; McKeage K
Drugs; 2014 Jan; 74(1):127-33. PubMed ID: 24297706
[TBL] [Abstract][Full Text] [Related]
2. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
4. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
Dhillon S
Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
[TBL] [Abstract][Full Text] [Related]
5. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
[TBL] [Abstract][Full Text] [Related]
6. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
7. Macitentan for the treatment of pulmonary arterial hypertension.
Kholdani CA; Fares WH; Trow TK
Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
[TBL] [Abstract][Full Text] [Related]
8. Macitentan for the treatment of pulmonary arterial hypertension.
Sood N
Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.
Sidharta PN; Treiber A; Dingemanse J
Clin Pharmacokinet; 2015 May; 54(5):457-71. PubMed ID: 25860376
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
11. Macitentan for the treatment of pulmonary arterial hypertension.
Spikes L; Williamson T; Satterwhite L
Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
[TBL] [Abstract][Full Text] [Related]
12. Development of macitentan for the treatment of pulmonary arterial hypertension.
Selej M; Romero AJ; Channick RN; Clozel M
Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
[TBL] [Abstract][Full Text] [Related]
13. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
15. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
Raja SG
Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
[TBL] [Abstract][Full Text] [Related]
16. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
18. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Martynyuk TV; Aleevskaya AM
Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
[TBL] [Abstract][Full Text] [Related]
19. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
Clozel M
Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
[TBL] [Abstract][Full Text] [Related]
20. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
